Biogen Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bearish -25

AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug

📉 Biogen's stock nosedived over 8% to $191.95 following the presentation of diranersen data at AAIC 2026.

💊 The Phase 2 trial showed a 26% slowing of cognitive decline at the 60 mg dose versus placebo after 26 weeks.

⚠️ An inverse dose-response was observed, with the 115 mg high-dose arm showing only 14% slowing of decline.

🧬 Diranersen is an antisense oligonucleotide that silences the MAPT gene to stop tau protein production entirely.

🚀 Biogen confirmed it will advance diranersen to Phase 3 despite missing the primary endpoint.

📊 The 26% clinical benefit was lower than the 27%-29% range seen in approved anti-amyloid therapies Leqembi and Kisunla.

🏆 Experts noted diranersen's data is superior to UCB's failed bepranemab monoclonal antibody approach.

🔬 The drug demonstrated a robust biomarker effect and clinical signal, validating the anti-tau hypothesis.

🤝 Biogen partnered with Ionis Pharmaceuticals to develop this unique gene-silencing therapy.

🧠 Eisai is advancing etalanetug in combination with Leqembi for dominantly inherited Alzheimer's disease.

🚀 Denali Therapeutics' DNL628 candidate targets the MAPT gene with a platform designed for superior brain penetration.

🔬 Arrowhead Pharmaceuticals' ARO-MAPT showed 70%-80% tau knockdown in nonhuman primates across deep brain structures.

💉 Eli Lilly is developing an intrathecally delivered siRNA molecule to knock down tau in Phase 1.

❓ Analysts and experts raised questions about the optimal dose of diranersen for subsequent studies.

🧪 The study confirmed that stopping upstream protein production can reverse tau pathology.

Bullish Signals
  • Diranersen validated the anti-tau hypothesis by showing a clear correlation between tau reduction and clinical benefit in patients.
  • The drug demonstrated a robust biomarker effect, distinguishing it from previous monoclonal antibody approaches that faced repeated failures.
  • Biogen's unique ASO mechanism silences the MAPT gene to prevent tau protein production entirely, addressing both intracellular and extracellular forms.
  • Experts praised the data as a significant win for the anti-tau approach compared to recent failures by UCB, Johnson & Johnson, and Eli Lilly.
  • The study de-risks similar programs from partners like Arrowhead Pharmaceuticals and Denali Therapeutics that target the same gene silencing mechanism.
Risk Factors
  • Diranersen missed its Phase 2 primary endpoint due to a puzzling inverse dose-response relationship where higher doses yielded less clinical benefit.
  • The 26% slowing of decline observed in the trial was on the lower end compared to the efficacy ranges of approved anti-amyloid therapies like Leqembi and Kisunla.
  • Analysts expressed skepticism regarding the robustness and replicability of the data set, leading to a significant stock price decline.
  • The inverse dose-response creates uncertainty about the optimal level of tau reduction and the correct dosing strategy for Phase 3 trials.
Full Analysis
At the Alzheimer's Association International Conference (AAIC) 2026, Biogen presented mid-stage data from its Phase 2 trial of diranersen, an antisense oligonucleotide developed with Ionis. The study validated the anti-tau hypothesis by demonstrating a correlation between tau reduction and clinical benefit in patients with Alzheimer's disease. However, the data revealed a puzzling inverse dose-response relationship where higher doses yielded less cognitive improvement compared to lower doses. Despite missing its primary endpoint due to this dose discrepancy, Biogen announced it will proceed to Phase 3 development. Wall Street reacted negatively to the presentation, causing Biogen's stock to drop over 8% to $191.95. Analysts noted that while the drug showed a 26% slowing of decline at the lowest dose, this was on the lower end compared to approved anti-amyloid therapies like Leqembi and Kisunla. The presentation highlighted diranersen's unique mechanism as an ASO that silences the MAPT gene to prevent tau protein production entirely, rather than targeting extracellular tau. This approach showed a robust biomarker effect and clinical signal, distinguishing it from recent failures of monoclonal antibody approaches by competitors like UCB and Johnson & Johnson. The news also contextualized Biogen's data within the broader anti-tau landscape, noting that other companies like Eisai, Denali Therapeutics, Arrowhead Pharmaceuticals, and Eli Lilly are advancing their own tau-targeting candidates. While ADFF experts praised the validation of the intracellular knockdown strategy, questions remain regarding the optimal dose for Phase 3 trials.